Software & Services is the fastest-growing line in the global immunoassay market, compounding at 9.2% a year and drawing revenue share away from the reagent products that have long defined the category. Its share of revenue climbs from 9% in 2025 to 11% in 2034, while ELISA Reagents & Kits, the largest line, eases from 24% to 21% over the same period. Contrive Datum Insights has published "Immunoassay Market Size, Share & Industry Analysis" (forecast 2026-2034), and the shift between these two product lines is among its clearest findings.
Size, Growth and What Pulls Software Ahead
The study sizes the global immunoassay market at USD 33.5 billion in 2025. It projects growth from USD 35.95 billion in 2026 to USD 60.95 billion by 2034, a compound annual growth rate of 6.82%. Software & Services runs well ahead of that pace, with its value rising from USD 3.02 billion to USD 6.71 billion.
The study ties the gap to testing volume. Rising chronic and infectious disease testing is the largest single contributor to growth over the forecast period, and its impact is rated high. The product lines most exposed to that volume move fastest, and Software & Services is the clearest case. Laboratory automation upgrades also matter. If they arrive faster than the base case assumes and reagent pricing holds firmer, 2034 revenue reaches USD 64.61 billion. If tender-based procurement squeezes reagent pricing further and automation upgrades stall in cost-constrained laboratories, it stops at USD 57.29 billion.
Other axes show the same pattern of a fast mover beside a large incumbent. Blood accounts for 68% of 2025 specimen revenue, yet Saliva grows fastest at 10.35%. Infectious Disease Testing leads applications with 32% of revenue, while Oncology grows fastest at 8.94%. Clinical Laboratories lead end-use at 36%, and Pharmaceutical and Biotech Companies grow fastest at 8.94%. By technology, Chemiluminescence Immunoassays (CLIA) hold the lead with 42% of 2025 revenue.
Regions and the Counterweight
North America leads with 36.1% of 2025 revenue, worth USD 12.08 billion, and reaches USD 20.42 billion by 2034. Asia Pacific gains ground, with its share moving from 25.3% in 2025 to 29.5% in 2034 as revenue grows from USD 8.48 billion to USD 17.98 billion. Middle East and Africa stays the smallest region throughout, at 5.9% of 2025 revenue and 5.7% by 2034. The United States is the largest single country market at USD 10.4 billion in 2025, or 31.04% of global revenue.
Against all this momentum sits the biggest line in the market. ELISA Reagents & Kits carries USD 8.04 billion of 2025 revenue, yet it grows at only 5.23%, below the market's 6.82%. That is why its share drifts down even as its dollar value rises. A buyer looking only at the size of the reagent base would miss where the growth is going, and a buyer looking only at software would miss where most of the revenue still sits.
The report segments the market across five axes (product, specimen, technology, application and end-use), with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.